Main Uses of Cleboril Pediatrico

Cleboril Pediatrico is a medication primarily used in pediatric medicine to manage functional gastrointestinal disorders. Its active ingredient, clebopride, belongs to a class of drugs known as orthopramides, which act as substituted benzamides with prokinetic properties.

The medication is frequently indicated for the treatment of symptoms associated with gastroesophageal reflux and functional digestive motility disorders. By influencing the movement of the digestive tract, it helps address underlying issues related to how food and liquids pass through the stomach and intestines.

Therapeutic Benefits

The primary benefit of this treatment is the improvement of gastric emptying and the coordination of digestive transit. Key areas of application include:

• Gastroesophageal Reflux: It helps manage the upward movement of stomach contents into the esophagus, which is a common occurrence in pediatric patients.
• Nausea and Vomiting: The medication is used to alleviate symptoms of nausea and prevent vomiting associated with functional digestive disturbances.
• Digestive Hypomotility: It is effective in cases where the stomach muscles do not contract sufficiently, leading to delayed digestion or a feeling of fullness.

Mechanism of Action

Cleboril Pediatrico works by accelerating the transit of the bolus through the stomach and the initial parts of the small intestine. It enhances the tone of the lower esophageal sphincter, which serves as a physical barrier against reflux, while simultaneously coordinating the contractions of the stomach (antrum) and the duodenum. This dual action facilitates a more efficient digestive process and reduces the time gastric contents remain in the stomach.

Regulatory References

1. Ficha Técnica Cleboril 500 microgramos comprimidos - CIMA

Who can and cannot use Cleboril Pediatrico?

The eligibility for Cleboril Pediatrico is strictly defined by official regulatory documentation, establishing numerous absolute exclusions and constraints based on age and pre-existing medical conditions.

The medicine is contraindicated for patients with:

• Gastrointestinal hemorrhage, obstruction, or perforation.
• Pre-existing neurological conditions such as epilepsy, Parkinson's disease, or any other extrapyramidal disorder.
• A documented history of tardive dyskinesia induced by other antidopaminergic agents.

---

Population	Eligibility Rule
Minimum Age	Approved for children starting from 1 year of age. Use in infants under 1 year is not recommended.
Organ Function	Use requires caution in patients with severe hepatic impairment or severe renal impairment.
Reproductive Status	Use is recommended to be avoided during both pregnancy and lactation.
Older Adults	Use requires caution due to increased susceptibility to certain neurological effects.

The restrictions enforce that the core eligible group is children from one year of age, and all use must be governed by the specific rules regarding pre-existing neurological and gastrointestinal conditions.

Interactions with other medicines and products

Official regulatory information identifies specific pharmacological classes and substances that interact with Clebopride Malate, the active ingredient in Cleboril Pediatrico.

Pharmacodynamic Interactions

Co-administration with other medicines that affect the central nervous system (CNS) can result in potentiation of effects:

Interacting Product Category	Official Interaction Description
CNS Depressants (Hypnotics, Anxiolytics, Narcotics)	May potentiate the sedative effects [Source AEMPS].
Antidopaminergic Agents (Phenothiazines, Butyrophenones)	May enhance effects on the central nervous system [Source AEMPS].
Monoamine Oxidase Inhibitors (IMAO)	Use may increase the risk of adverse reactions [Source AEMPS].

Conversely, some medicines may compromise the product's primary action:

• Anticholinergics and Narcotic Analgesics (Opioids) may neutralize the prokinetic action of Clebopride on gastrointestinal motility [Source AEMPS].

Exposure and Substance Interactions

• Impact on Co-administered Drug Exposure: Clebopride is documented to decrease the effects of both Digoxin and Cimetidine [Source AEMPS].
• Alcohol: Alcohol must be avoided as it is officially noted to potentiate the sedative effects of the medicine [Source AEMPS].
• Other Interactions: No specific interactions with food, supplements, or herbal products are explicitly documented in the regulatory label reviewed.

Population-Specific Notes

The official documents caution that the effect of Clebopride may be increased or prolonged in patients with severe hepatic or renal insufficiency [Source AEMPS]. No mandatory time separation requirements for co-administration are specified in the regulatory text.

Dual Modulation of Dopamine and Serotonin Signaling

Cleboril Pediatrico's mechanism involves acting as an antagonist (blocker) at peripheral and central Dopamine D2 receptors and as an agonist (activator) at peripheral Serotonin 5- HT4 receptors. This dual interaction modulates the central vomiting cascade and peripheral gastrointestinal motility.

Central Mechanism: Modulation of the Emetic Response

The drug blocks D2 receptors in the Chemoreceptor Trigger Zone (CTZ) of the brain, a regulatory area sensitive to emetic chemical signals. By suppressing D2 signaling in the CTZ, the mechanism modulates the major neural cascade involved in initiating the emetic response.

Peripheral Mechanism: Enhancement of Gastrointestinal Motility

In the gut's enteric nervous system, the combined D2 blockade and 5- HT4 activation enhance the release of acetylcholine, the primary neurotransmitter for muscle contraction. This action increases the tone and organization of peristalsis (involuntary muscle contractions), resulting in accelerated gastric emptying and enhanced propulsive action within the digestive tract.

Oral Administration and Dosing Principles

Cleboril Pediátrico is a specialized formulation intended exclusively for the oral route of administration, provided as an oral solution in drops. This liquid dosage form is designed for its specific patient group, which includes children aged 1 to 12 years. The administration protocol structures use around precise, fractional dosing.

---

Frequency and Measurement

The total daily amount is divided and administered in a regimen of three times per day. For proper usage, the medicine is taken before the main meals, aligning its timing with the digestive process.

Dosing is primarily based on the child’s body weight. The daily intake is calculated to fall between 12.5 and 15.62 micrograms of clebopride per kilogram of body weight. The usage constraints specify that the total dose must not exceed 18.75 micrograms per kilogram of body weight in any 24-hour period. To ensure this accuracy, it is required to use the exclusive calibrated syringe included with the package for all measurements.

---

Administration Conditions

For consumption, the drops can be administered directly or may be dissolved in half a glass of water. Furthermore, procedural guidelines advise using the medication with caution in children who have severe hepatic or renal impairment.

Research evidence / Overview of studies for Cleboril Pediatrico

Research Base for Nausea and Vomiting

Research has explored the use of clebopride malate in studies examining episodic or acute symptom patterns related to vomiting and nausea. The evidence base includes short-term randomized controlled trials (RCTs) and various specialized clinical investigations that evaluated whether symptoms change over time. These studies often focused on outcomes related to episodic or acute changes, such as the frequency and severity of vomiting episodes.

Studies report measurements in outcomes related to physical discomfort in patients, including those with conditions associated with acute or disruptive episodes, such as those caused by chemotherapy. However, evidence related to the overall certainty of these findings remains subject to the limitations of existing data. Long-term effects are not fully established, as follow-up durations were limited, focusing mainly on immediate, acute relief.

---

Research Base for Functional Digestive Issues

The research for clebopride also studied functional digestive issues, which are conditions marked by functional limitations such as slow stomach emptying. Studies explored outcomes reflecting daily functioning or activity level, including double-blind, placebo-controlled trials. The outcomes measured in this domain included objective functional measurements and subjective changes in symptom clusters like postprandial fullness, bloating, and discomfort.

Studies report patterns observed during the study period related to these symptoms in the observed populations. What remains uncertain is the comprehensive nature of this research; Comparative evidence is lacking for some of the most common functional GI symptoms in the full spectrum of children. Furthermore, the specific data for younger children with chronic or recurring functional disorders remain somewhat less consistent.

---

Research in the Pediatric Population

Given the Pediatrico designation, the research base includes studies specifically applied in settings that involve the target audience—infants and children. This is a special population where evidence is crucial, and the studies monitored acute changes and were applied in research contexts involving fluctuating or unstable symptoms. Research has studied the compound in anti-emetic contexts, including trials with children. These findings help contextualize how patients reported their experience when the compound was used in research exploring short-term symptom changes. However, it must be noted that results apply only to the populations studied, and findings describe group patterns, not personal outcomes.

---

What is Still Uncertain About Cleboril Pediatrico

Several gaps exist in the current research landscape. Long-term effects are not fully established, and there is limited information regarding the need for, or characteristics of, prolonged use, especially in the growing pediatric population. Additionally, the evidence quality varies across studies, and many of the older comparative trials may not align with current standards for large-scale, comprehensive RCTs. Research provides limited information for long-term outcomes related to growth or symptom recurrence over the course of a child's development.

Key Studies & References

1. Clebopride in the treatment of nausea and vomiting in patients with advanced cancer.
2. Ficha Técnica Cleboril 500 microgramos comprimidos (Cleboril Summary of Product Characteristics) - CIMA (Spanish Agency of Medicines and Medical Products)

Common questions about Cleboril Pediatrico (FAQ)

Q: What is Cleboril Pediatrico actually for? Does it help with sleep or anxiety?

A: Cleboril Pediatrico is officially indicated for regulating digestive flow and suppressing nausea and vomiting. The regulatory label lists sleepiness ( Somnolencia) as a documented adverse reaction, which is a central nervous system (CNS) effect. The medicine is not indicated for treating sleep or anxiety, and is generally not studied for these purposes.

Q: Can Cleboril Pediatrico cause problems if my child takes a common over-the-counter allergy medicine?

A: Official product information warns that concurrent use with medications classified as CNS depressants (drugs that slow brain activity) may potentiate the sedative effects. Because many non-prescription allergy medications may contain ingredients classified as CNS depressants, the label indicates that an increase in sedation is possible when taken concurrently.

Q: Is there a maximum age limit for using the 'Pediatrico' version of this drug?

A: The Pediátrico formulation is specifically designed for use in children aged 1 to 12 years. This age range defines the population for which the specialized liquid drop dosage form is intended.

Q: Are there any specific foods or drinks that should be avoided when taking this medication?

A: Official information advises that alcohol should be avoided when using this medication, as regulatory information notes it may potentiate the sedative effects. No specific interactions with food or non-alcoholic drinks are explicitly documented in the official regulatory label reviewed.

Q: Does taking Cleboril Pediatrico affect a child's school performance or concentration?

A: Official safety documents list adverse reactions that include sleepiness ( Somnolencia) and apathy ( Apatía). As these are effects on the central nervous system (CNS), they may potentially affect alertness and concentration.

Q: How long can a child safely stay on Cleboril Pediatrico, according to the research?

A: Clinical research primarily involved short-term randomized controlled trials focused on acute symptoms. Regulatory documents state that the long-term effects are not fully established, and there is limited information regarding the characteristics of prolonged use.

Q: I saw a comment saying this drug is related to an antipsychotic. Is that true?

A: The active ingredient, Clebopride, is officially classified as a dopamine D2 receptor antagonist. This mechanism of action—blocking dopamine receptors—is shared by a class of medications called antidopaminergic agents, which includes some antipsychotic drugs.

Q: Is Cleboril Pediatrico meant to be taken for a short time or long-term?

A: The evidence base for this medicine is derived from short-term clinical trials focusing on acute relief of symptoms. Official regulatory documents indicate that the long-term effects are not fully established in the pediatric population.

Q: What are the non-serious side effects that are frequently reported?

A: The official label lists non-serious adverse reactions including sleepiness ( Somnolencia), apathy ( Apatía), and dry mouth ( Sequedad de boca). The more clinically significant reactions, such as motor disturbances, are documented as uncommon ( Poco frecuentes).

Q: Can Cleboril Pediatrico be used for toddlers under the age of 2?

A: According to the official product information, the medicine is approved for use in children starting from 1 year of age and up to 12 years.

Q: Is it common to feel jittery or restless after starting Cleboril Pediatrico?

A: The official label documents reversible motor disturbances and extrapyramidal symptoms (clinical terms for effects like restlessness). These motor effects are noted as being more frequent in children and are usually observed at the beginning of the treatment.

Q: Does Cleboril Pediatrico have an impact on growth and development in children?

A: Regulatory documentation notes that research provides limited information for long-term outcomes related to growth and symptom recurrence over the course of a child's development. Long-term effects are not fully established.

Q: How long does it typically take to see any kind of difference after starting Cleboril Pediatrico?

A: Clinical literature associated with the regulatory review indicates that the onset of action of the active ingredient, clebopride, usually occurs within 30 minutes to an hour after ingestion.

Q: If I miss a dose of Cleboril Pediatrico, what does the official information recommend?

A: Official labels do not typically provide specific instructions for handling a forgotten dose, as this guidance should come from the prescribing healthcare professional. General regulatory safety statements advise against taking a double dose to make up for a missed one.

Q: Does this medicine have a known 'black box' warning from regulatory agencies?

A: Searches of major international regulatory safety databases for the active ingredient (clebopride) do not indicate that an officially required Boxed Warning (sometimes called a Black Box Warning) is in place.

Q: Is Cleboril Pediatrico considered a narcotic or a controlled substance?

A: The active ingredient, Clebopride, is classified as a dopamine antagonist/prokinetic agent. It is not listed on major international or US regulatory schedules as a narcotic or a controlled substance.

Q: What do I do if my child has a severe allergic reaction to Cleboril Pediatrico?

A: In the event of any severe or suspected allergic reaction, regulatory guidance mandates that the medication be discontinued and emergency medical treatment be sought immediately.

Q: Does Cleboril Pediatrico have the potential for dependence or addiction?

A: Clebopride is generally not reported to have habit-forming tendencies in associated clinical literature. It is not listed on controlled substance schedules by regulatory bodies.

Q: Can Cleboril Pediatrico make existing anxiety symptoms worse when starting out?

A: The medicine is a dopamine antagonist that affects the central nervous system (CNS). While the label notes CNS effects like apathy and motor disturbances, it is appropriate for individuals with pre-existing anxiety symptoms to consult a healthcare professional regarding use.

Q: Are there any warnings for children with known heart conditions?

A: Clinical studies referenced in regulatory reviews suggest that the drug is not typically associated with cardiac side effects at the prescribed dose. However, clinical literature cautions that supratherapeutic concentrations (exceeding the recommended dose) may have the potential to affect heart rhythm.

Q: What should parents know about signs of an overdose with Cleboril Pediatrico?

A: The official product information mandates seeking emergency medical treatment immediately in case of a suspected overdose. Clinical data warns that exceeding the therapeutic dose may lead to serious effects, including potential disturbances in heart rhythm.

Q: Can children with known allergies to certain dyes or fillers use this drug?

A: The regulatory label provides a complete list of all excipients (inactive ingredients, fillers, and dyes) in the formulation. A known allergy to any of these listed inactive ingredients would be considered a contraindication, necessitating consultation with a healthcare professional.

Q: What is the half-life of Cleboril Pediatrico, as described in pharmacokinetics data?

A: The official document on pharmacokinetic properties describes the drug's absorption, distribution, metabolism, and elimination/excretion. This information includes data used to determine the drug's half-life (the time it takes for the body to reduce the amount of drug by half).

Q: How is the safety of Cleboril Pediatrico monitored after it has been approved and released?

A: All regulatory agencies require mandatory post-marketing surveillance (pharmacovigilance) and reporting of adverse events. This system continuously monitors the safety profile of the medicine after its approval and release to the public.

Storage and Disposal Requirements

The conservation of Cleboril Pediatrico (Clebopride oral solution) does not require special storage conditions, such as refrigeration or specific protection from light or moisture, according to regulatory documentation. The product remains stable when stored at standard ambient temperature.

Official Constraints

Requirement	Official Instruction
Expiration	Do not use this medicine after the printed expiration date (CAD) on the carton.
Child Safety	Keep this medicine out of the sight and reach of children.
Disposal	Do not dispose of via wastewater or household waste. Unused or expired medication must be returned to a pharmacy collection point for proper handling.

These instructions ensure both product stability until the expiry date and environmentally safe disposal of pharmaceutical waste.